异动解读|BioNTech SE盘中下跌5.06%,乳腺癌新药细分人群获益表述偏谨慎

行情直击
Nov 06

11月6日,BioNTech SE盘中下跌5.06%,报86.17美元/股,成交额5816.14万美元。

消息面上,公司最新表示,曲妥珠单抗帕米替康在HR+/HER2-low乳腺癌人群中的获益可能有限,正与DualityBio讨论BLA申报计划。此前该药III期试验虽达到无进展生存期主要终点,但总生存期数据尚未成熟,且公司曾披露少量严重及致命不良事件、间质性肺病发生率高于既往试验,令市场对其商业化预期与适用人群范围保持谨慎。

(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10